Comgest Global Investors S.A.S. Has $5.58 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Comgest Global Investors S.A.S. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,898 shares of the company’s stock after selling 856 shares during the quarter. Comgest Global Investors S.A.S.’s holdings in Novo Nordisk A/S were worth $5,584,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in NVO. Blair William & Co. IL raised its position in shares of Novo Nordisk A/S by 12.9% during the first quarter. Blair William & Co. IL now owns 71,036 shares of the company’s stock worth $9,121,000 after acquiring an additional 8,126 shares during the last quarter. Nwam LLC raised its position in shares of Novo Nordisk A/S by 51.3% during the first quarter. Nwam LLC now owns 3,831 shares of the company’s stock worth $488,000 after acquiring an additional 1,299 shares during the last quarter. First Foundation Advisors raised its position in shares of Novo Nordisk A/S by 3.1% during the first quarter. First Foundation Advisors now owns 7,416 shares of the company’s stock worth $952,000 after acquiring an additional 223 shares during the last quarter. Nicolet Advisory Services LLC raised its position in shares of Novo Nordisk A/S by 5.2% during the first quarter. Nicolet Advisory Services LLC now owns 2,777 shares of the company’s stock worth $347,000 after acquiring an additional 138 shares during the last quarter. Finally, Spirepoint Private Client LLC bought a new position in shares of Novo Nordisk A/S during the first quarter worth about $271,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 3.4 %

Novo Nordisk A/S stock traded down $3.58 during mid-day trading on Friday, reaching $101.74. The stock had a trading volume of 8,076,248 shares, compared to its average volume of 4,457,389. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The stock’s 50-day simple moving average is $118.58 and its 200-day simple moving average is $129.58. The firm has a market capitalization of $456.56 billion, a PE ratio of 32.93, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of research analyst reports. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.